Table 2.
Elecsys® Zika IgG assay diagnostic specificity in samples from non-endemic areas.
| Cohort | N | Positive Samples after Resolution | Negative Samples after Resolution | Positive Discrepant Samples after Resolution | Specificity (95% CI) |
|---|---|---|---|---|---|
| Samples from Latin America before Zika epidemics | 94 | 2 | 92 | 0 | 100 (96.07–100) |
| Pregnant women in Europe | 500 | 0 | 500 | 0 | 100 (99.26–100) |
| European blood donors | 532 | 4 | 526 | 2 | 99.62 (98.64–99.95) |
| European blood donors with high TBE vaccination status | 559 | 0 | 559 | 0 | 100 (99.34–100) |
| Total | 1685 | 6 | 1677 | 2 | 99.88 (99.57–99.99) |